Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10501682 | 0.89 | ADRA2A (0.50) | PIN1ADRA1AIDO1TAS1R3TAS1R1 | |
| SCHEMBL15846513 | 0.87 | PIN1 (0.47) | PIN1ADRA1AIDO1PDPK1TAS1R3 | |
| SCHEMBL14283849 | 0.86 | DRD1 (0.47) | PIN1ADRA1ADRD1 | |
| SCHEMBL9316636 | 0.82 | CETP (0.43) | PIN1ADRA1AIDO1PDPK1TAS1R3 | |
| SCHEMBL23003774 | 0.81 | PIN1 (0.50) | PIN1TAS1R3TAS1R1TAS1R2DRD1 | |
| SCHEMBL4275619 | 0.78 | PIN1 (0.43) | PIN1ADRA1AIDO1PDPK1TAS1R3 | |
| SCHEMBL1871239 | 0.77 | SIGMAR1 (0.47) | ADRA1AIDO1PDPK1SIGMAR1CYP11B2 | |
| SCHEMBL28306252 | 0.77 | ALOX15 (0.46) | PIN1ADRA1ADRD1 | |
| SCHEMBL14283889 | 0.77 | BACE1 (0.48) | PIN1ADRA1ADRD1 | |
| SCHEMBL2984209 | 0.76 | IDO1 (0.48) | ADRA1AIDO1PDPK1SIGMAR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5576139-A | EXCELLENT RESOLUTION, SENSITIVITY, HEAT RESISTANCE AND DEVELOPABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1996-11-19 | — | — | US | claimed |
| EP-0160508-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-31 | — | — | EP | claimed |
| CN-115449262-A | Marking composition | 桑福德有限合伙人公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-105579438-A | Compounds and methods for skin repair | ALLERGAN INC | 2016-05-11 | — | — | CN | disclosed |
| CN-105130758-A | Method for preparing bisphenol A by adopting combined process of suspension crystallization and falling film crystallization | NANTONG XINGCHEN SYNTHETIC MATERIAL CO LTD | 2015-12-09 | — | — | CN | disclosed |
| CN-101855213-B | Therapeutic compounds | ALLERGAN INC | 2014-09-10 | — | — | CN | disclosed |
| CN-101877966-A | Farnesoid X receptor agonists | SMITHKLINE BEECHAM CORP | 2010-11-03 | — | — | CN | disclosed |
| CN-100516011-C | Production of bisphenol A with reduced isomer formation | BAYER MATERIALSCIENCE AG (DE) | 2009-07-22 | — | — | CN | disclosed |
| CN-1918097-A | Production of bisphenol A with reduced isomer formation | BAYER MATERIALSCIENCE AG (DE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1713752-A1 | PRODUCTION OF BISPHENOL A WITH A REDUCED ISOMER FORMATION | Bayer MaterialScience AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| CN-1720236-A | 4-substituted benzimidazoles and their use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-01-11 | — | — | CN | disclosed |
| WO-2005075396-A1 | PRODUCTION OF BISPHENOL A WITH A REDUCED ISOMER FORMATION | BAYER MATERIALSCIENCE AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176918-A1 | Production of bisphenol a with reduced isomer formation | BAYER MATERIALSCIENCE AG (DE) | 2005-08-11 | — | — | US | disclosed |
| US-5576139-A | EXCELLENT RESOLUTION, SENSITIVITY, HEAT RESISTANCE AND DEVELOPABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0342758-A1 | Preparation of bisphenols | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176918-A1 | Production of bisphenol a with reduced isomer formation | CYP4A11, CYP19A1, SHBG | PIN1 893/4885ADRA1A 560/4885IDO1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.